FDA approves Kerendia in chronic kidney disease (CKD) associated with type 2 diabetes – Bayer HealthCare
Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.
